BIOREPERIA AB

Their core work

BioReperia is a small Swedish biotech SME based in Linköping that specialises in biological research tools and models for drug discovery, with a clear focus on ocular (eye) therapeutics and CNS-related conditions. Their participation in two consecutive MSCA-RISE networks indicates they provide a specific biological capability — most likely cell-based or tissue-based assay models — that academic and industrial consortia in drug development find valuable enough to include as a partner. The company operates at the interface of research and commercial application, as signalled by the "Commercial & Research Opportunity" framing of their most recent project. Given their location in Linköping's life sciences ecosystem and the recurring ocular theme across both projects, they likely occupy a niche in eye-disease biology or drug screening platforms for ophthalmic indications.

What they specialise in

How they've shifted over time

BioReperia's two projects trace a path from broad multi-indication drug discovery (oncology + eye, 3D delivery networks, 2017-2022) toward a tighter mechanistic focus on a specific biological pathway — cysteinyl leukotriene signalling — in ocular and CNS disease (2021-2024). The shift is from platform-level participation in a drug-delivery network to a commercially framed collaboration around a defined molecular target, suggesting the company is narrowing toward translatable, market-facing science. The overlap period between the two projects (2021-2022) indicates continuity of engagement rather than a hard pivot, but the direction is clearly toward greater specificity and commercial relevance.

BioReperia is moving from broad drug-discovery network participation toward focused, commercially positioned research on specific inflammatory pathways in eye and neurological disease — a trajectory that suits partners seeking translatable biology rather than exploratory platform work.

How they like to work

BioReperia has never led an H2020 project; both participations are as a partner within large MSCA-RISE exchange networks, which are by design multi-institutional and geographically distributed. With 28 unique partners across 10 countries from just two projects, they operate in unusually large consortia relative to their size, which is typical for RISE networks but also suggests they are comfortable with complex, multi-party collaborations. Their role is that of a specialised contributor — they bring a specific biological capability that the broader network lacks rather than providing organisational leadership.

Despite only two projects, BioReperia has touched 28 distinct partner organisations across 10 countries, a high partner-per-project ratio driven by the MSCA-RISE format. Their network is broadly European with no identifiable geographic concentration beyond the Swedish base.

What sets them apart

BioReperia occupies an unusual niche as a commercial SME that consistently appears in academic MSCA-RISE drug-discovery consortia focused on ophthalmology — a combination that is rare among Swedish biotechs of their size. Their recurring presence in eye-disease projects across multiple funding cycles suggests they hold proprietary biological models or assay capabilities that are difficult to replicate elsewhere, making them a valuable specialist rather than a generic industry partner. For any consortium building a drug-discovery or pharmacological programme touching ocular or neurological inflammation, they represent an industrial anchor with directly relevant biological expertise.

Highlights from their portfolio

• CRYSTAL3
  The most recent and only funded project, it targets a specific molecular pathway (cysteinyl leukotriene signalling) across two high-value therapeutic areas simultaneously — ocular disease and CNS dysfunction — with an explicit commercial framing that signals translational intent.
• 3D NEONET
  Their founding H2020 project, spanning five years (2017-2022), placed BioReperia inside a European drug discovery and delivery network for both oncology and eye therapeutics, establishing the multi-indication biological platform that underpins their later specialisation.